Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has announced that Lipitor 80mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 27% in patients with heart disease who had previous coronary bypass surgery compared with patients taking the 10mg dose of Lipitor.
Subscribe to our email newsletter
This analysis, designed and completed following the closure of the five-year Treating to New Targets (TNT) study. The TNT study was an investigator led trial coordinated by independent steering committee and funded by Pfizer. The primary endpoint was the reduction of major cardiovascular events, including death from heart disease, non-fatal heart attacks, resuscitated cardiac arrest, and fatal or non-fatal strokes.
Intensive Lipitor therapy also provided a significant 30% reduction in the need for either repeat coronary bypass surgery or angioplasty, another type of interventional heart surgery, compared with Lipitor 10mg. Both doses of Lipitor (80mg and 10mg) were well-tolerated in patients with prior coronary bypass surgery, and the safety profile of Lipitor 80mg was comparable to Lipitor 10mg, a finding that was consistent with the overall TNT population.
Rochelle Chaiken, vice president of global cardiovascular and metabolic medical team at Pfizer, said: “Although these patients continue to be at an increased risk for major cardiovascular events and repeat heart surgery, statins are considerably underused. This analysis highlights not only the importance of treating, but also treating aggressively with Lipitor 80mg.”